Company Description
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases.
The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration.
The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate.
BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Sep 26, 2024 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 62 |
| CEO | Kristen Fortney |
Contact Details
Address: 5885 Hollis Street, Suite 370 Emeryville, California 94608 United States | |
| Phone | 510 806 1445 |
| Website | bioagelabs.com |
Stock Details
| Ticker Symbol | BIOA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001709941 |
| CUSIP Number | 09077V100 |
| ISIN Number | US09077V1008 |
| Employer ID | 47-4721157 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kristen Fortney Ph.D. | Co-Founder, Chief Executive Officer, President, Treasurer, Secretary and Director |
| Dr. Eric Morgen M.D. | Co-Founder, Chief Operating Officer and Director |
| Dr. Paul D. Rubin M.D. | Chief Medical Officer and Executive Vice President of Research |
| Dr. Dov A. Goldstein M.B.A., M.D. | Chief Financial Officer |
| Shane Barton CPA | Senior Vice President of Finance and Accounting |
| Rusty Montgomery Ph.D. | Senior Vice President of Research |
| Julie Gammelgard | Senior Vice President of People |
| Dr. Peng Leong M.B.A., Ph.D. | Chief Business Officer and Therapeutic Area Head of Brain Aging |
| BJ Sullivan Ph.D. | Chief Strategy Officer |
| Ann C. Neale RN BSN | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | SCHEDULE 13G | Filing |
| Apr 21, 2026 | ARS | Filing |
| Apr 21, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 21, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2026 | 144 | Filing |
| Mar 24, 2026 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2026 | 10-K | Annual Report |
| Mar 24, 2026 | 8-K | Current Report |
| Mar 2, 2026 | 144 | Filing |